As Glenn Mattes, CEO of TFF Pharmaceuticals, told BioSpace, “The persistent rise of COVID-19 cases, including among the vaccinated, has understandably impacted the morale of both the biopharma industry and the broader community.”

MeiraGTx Holdings PLC said it received a $30 million payment from Janssen Pharmaceuticals Inc., part of the Janssen Pharmaceutical Cos. of Johnson & Johnson, for a clinical milestone in a Phase 3 trial of botaretigene sparoparvovec.

The US Food and Drug Administration has cleared an Investigational New Drug application allowing MindMed to move forward with a phase 2b dose-optimization trial of MM-120 for the treatment of generalized anxiety disorder (GAD).

To address both of these challenges, TFF Pharmaceuticals has developed a process called Thin Film Freezing (TFF), which produces drugs that are highly soluble and stable in a powder form, for a variety of applications, including delivery to the lung. 

Recce’s lead drug candidate, called R327, is a synthetic polymer that is currently undergoing Phase I trials for sepsis, with an ongoing Phase I/II trial for burn wound infections. According to Graham, R327 utilizes multiple inhibitory mechanisms that work in “a synergistic compounding fashion.” These mechanisms include adenosine triphosphate (ATP) inhibition, cell membrane permeabilization and bacterial cell division inhibition.

San Jose-based Anixa Biosciences is looking to keep “retired” proteins from coming back and causing havoc to the body—particularly in the form of triple-negative breast cancer and ovarian cancer.

You also need to be strong in other parts of your body if you want to keep active. In your knees, you need to maintain strength, but also flexibility and muscular balance, says Fred Cushner, M.D., an orthopedic surgeon at the Hospital for Special Surgery in New York City and chief medical officer for Canary Medical.